Kennedy Capital Management LLC Takes Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Kennedy Capital Management LLC bought a new position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 145,734 shares of the company’s stock, valued at approximately $1,988,000.

Other large investors have also recently added to or reduced their stakes in the company. Gladius Capital Management LP lifted its position in iTeos Therapeutics by 48.7% during the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock worth $34,000 after acquiring an additional 1,026 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in shares of iTeos Therapeutics by 4.9% in the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in iTeos Therapeutics by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,877 shares of the company’s stock worth $94,000 after acquiring an additional 2,737 shares during the period. Federated Hermes Inc. raised its stake in iTeos Therapeutics by 4,648.4% during the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after purchasing an additional 2,882 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in iTeos Therapeutics by 53.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,826 shares of the company’s stock valued at $97,000 after purchasing an additional 3,069 shares during the period. Institutional investors own 97.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ITOS. HC Wainwright boosted their price objective on iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Wedbush reissued an “outperform” rating and issued a $21.00 price target on shares of iTeos Therapeutics in a report on Monday, June 17th.

iTeos Therapeutics Trading Up 1.1 %

NASDAQ:ITOS traded up $0.19 during mid-day trading on Wednesday, hitting $17.66. The stock had a trading volume of 50,315 shares, compared to its average volume of 347,931. iTeos Therapeutics, Inc. has a twelve month low of $8.20 and a twelve month high of $18.75. The company’s 50 day simple moving average is $16.13 and its 200 day simple moving average is $13.28.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Friday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.05). Sell-side analysts forecast that iTeos Therapeutics, Inc. will post -4.57 earnings per share for the current year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.